Iselin NJ, October 30, 2007 – Pharmos Corporation (Nasdaq: PARS) today reported results for the third quarter ended September 30, 2007. Net loss decreased 17% to $3.5 million, or $0.14 per share, for the third quarter 2007, from a net loss of $4.2 million, or $0.22 per share, in the third quarter 2006. Cash and short-term investments totaled $13.9 million at September 30, 2007. The decrease […]
Iselin NJ, October 30, 2007 – Pharmos Corporation (Nasdaq: PARS) announced today it is undertaking a second phase of restructuring as it continues to optimize the balance between cash resources and its most promising scientific research and development programs. This second phase involves a workforce reduction from 23 to 8 employees in its Israeli subsidiary, Pharmos Ltd. The Company does not expect a material charge against […]
Iselin NJ, September 28, 2007 – Pharmos Corporation (Nasdaq: PARS) today announced that it received notice on September 26, 2007 from The Nasdaq Stock Market that the minimum bid price of its common stock had fallen below $1.00 for 30 consecutive business days and that Pharmos was therefore not in compliance with Marketplace Rule 4310(c)(4). In accordance with the Nasdaq Marketplace Rule 4310(c)(8)(D), Pharmos has until […]
Iselin NJ, September 10, 2007 – Pharmos Corporation (Nasdaq: PARS) announced today it has issued the below Letter to Shareholders as part of its proxy materials for its annual meeting scheduled for October 24, 2007. Pharmos is among the first corporate issuers able to take advantage of the recently enacted SEC “Notice and Access Rule,” which allows companies to post proxy materials on the internet rather […]
Restructuring and Cost Reduction Plan Implemented in Early August 2007 Iselin NJ, August 8, 2007 – Pharmos Corporation (Nasdaq: PARS) today reported results for the second quarter ended June 30, 2007. The Company recorded a net loss of $4.6 million, or $0.18 per share, for the second quarter 2007 compared to a net loss of $4.1 million, or $0.21 per share, in the second quarter 2006. […]
Proof-of-Concept Study to Evaluate Safety and Analgesic Efficacy in Osteoarthritis Pain Iselin NJ, June 27, 2007 – Pharmos Corporation (Nasdaq: PARS) announced today that patient screening has commenced in its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% diclofenac. The trial will compare the safety and analgesic efficacy of the diclofenac NE cream with placebo in approximately 126 subjects […]
Trial to Evaluate Safety and Efficacy of Dextofisopam, a Novel First-in-Class Compound Iselin NJ, June 20, 2007 – Pharmos Corporation (Nasdaq: PARS) announced today patient screening has commenced in its Phase 2b clinical trial of dextofisopam, which is expected to enroll approximately 480 female patients with diarrhea-predominant or alternating irritable bowel syndrome (d- and a-IBS). IBS is a chronic and sometimes debilitating condition that affects roughly […]
Iselin NJ, June 7, 2007 – Pharmos Corporation (Nasdaq: PARS) today announced that on May 31, 2007, its counsel entered into an agreement with plaintiffs’ legal counsel to settle several class action lawsuits commenced starting in January 2005 and currently pending in the U.S. District Court for the District of New Jersey. The lawsuits relate to statements purportedly made by Pharmos and its officers regarding the […]
Iselin NJ, May 10, 2006 – Pharmos Corporation (Nasdaq: PARS) today reported results for the first quarter ended March 31, 2007. The Company recorded a net loss of $4.8 million, or $0.19 per share, for the first quarter 2007 compared to a net loss of $3.0 million, or $0.16 per share, in the first quarter 2006. Cash and short-term investments totaled $22.1 million at March 31, […]
Iselin NJ, May 8, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today that its Chief Executive Officer, Elkan Gamzu, Ph.D., will present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference on Tuesday, May 15, 2007 at 10:05 AM Central Europe Daylight Time (GMT +2:00, or 4:05 AM Eastern Daylight Time). The conference is taking place May 14-15, 2007 at Le Meridien Beach […]